INTRODUCTION {#s1}
============

Progesterone (P~4~) and estradiol (E~2~) are major ovarian steroid hormones crucial for the development and homeostasis of the female reproductive tract (i.e., uterus, cervix, and vagina) \[[@R1]\]. P~4~ and E~2~ function through progesterone receptor (PR) and estrogen receptor (ER), respectively. PR and ER are ligand−dependent transcription factors belonging to the nuclear receptor superfamily \[[@R1]\]. ERα and ERβ are encoded by *Esr1* and *Esr2,* respectively \[[@R2]\]. ERα is the major ER subtype in the female reproductive tract of mice and humans \[[@R2]--[@R4]\]. ERα is composed of several distinct functional domains, N−terminal activation function 1 (AF1), DNA−binding domain (DBD), a hinge region, and C−terminal ligand−binding domain containing the AF2. ERα activates its target gene expression by binding to estrogen response elements (EREs) through its DBD (classical mechanism) or other transcription factor (e.g., AP-1 and Sp-1) binding sites through protein−protein interactions (tethering mechanism) \[[@R2]\]. The *Pgr* gene coding for PR is a well−known ERα target gene in the female reproductive tract \[[@R1], [@R5]\]; however, the mechanism of *Pgr* activation by ERα is poorly understood. Reporter assays using isolated regulatory sequences of the *PGR* gene have implicated both classical and tethering mechanism in the transcriptional activation of *PGR* in MCF7 breast cancer cells \[[@R6]--[@R9]\]. However, it is unclear whether it is relevant to the normal female reproductive tract and whether both pathways are important in the natural chromatin context.

During the female sexual cycle in humans and rodents, an E~2~ surge promotes and a P~4~ surge inhibits epithelial cell proliferation in the reproductive tracts \[[@R10]\]. The uterine and vaginal epithelia consist of columnar and squamous epithelial cells, respectively. The cervical epithelium, however, is composed of columnar and stratified squamous epithelial cells \[[@R11]\]. The hormone−mediated regulation of epithelial cell proliferation in the reproductive tracts involves crosstalk between the stromal and epithelial compartment \[[@R12]\]. Epithelial ERα is dispensable for E~2~−induced proliferation of uterine columnar epithelial cells \[[@R13]\]. Stromal ERα is required for squamous epithelial cell proliferation in the cervix and vagina \[[@R14]\]. Epithelial PR is dispensable for P~4~−induced suppression of epithelial cell proliferation in the uterine tissue recombinants derived from neonatal mice \[[@R15]\]. P~4~ suppresses apoptosis in the uterine epithelium, which is mediated by stromal PR \[[@R16]\]. While PR is expressed in the cervical stroma and epithelium \[[@R17]\], knowledge on the function of PR and effects of P~4~ in the cervix is limited.

Using knock−in mice expressing mutant ERα lacking activities of DBD, AF1, or AF2, we show that all three domains are required for upregulation of *Pgr* in the cervical epithelium and vagina. We also show that AF1 is dispensable for upregulation of *Pgr* in the cervical and uterine stroma. Unlike the uterus, P~4~ promotes epithelial apoptosis in the cervix and vagina. P~4~ inhibits E~2~−induced cervical and vaginal squamous cell proliferation. Using epithelial *Pgr*−deficient mice, we demonstrate that epithelial PR is required for P~4~−induced apoptosis and suppression of cell proliferation in the cervical and vaginal epithelium. Our results are the first to show different functions and regulation of epithelial PR in the cervix, vagina, and uterus under the same hormonal condition.

RESULTS {#s2}
=======

Histological features of the female reproductive tract lacking epithelial PR {#s2_1}
----------------------------------------------------------------------------

To interrogate a role of epithelial PR in responses of the female reproductive tract to P~4~, we made use of *Wnt7a−Cre/Pgr^f/f^* mice (referred to as *Pgr^ed/ed^* hereafter; ed, epithelial deletion). In these mice, PR expression was ablated in the epithelium, but not stroma, of the cervix, vagina, and uterus (Figure [1A](#F1){ref-type="fig"}). To characterize epithelial PR functions under the same hormonal condition, we treated ovariectomized mice with E~2~ and P~4~ for 7 days. Seven−day treatment with E~2~ was required for the entire cervical epithelia to reach the full thickness ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"}). Regions of the uterus, cervix, and vagina that were analyzed throughout the study are shown in Figure [1B](#F1){ref-type="fig"}. The cervical epithelia of vehicle−treated *Pgr^f/f^* and *Pgr^ed/ed^* mice were thin (13.2 μm in average) and composed of 2−3 cell layers (Figure [1C](#F1){ref-type="fig"}). E~2~ increased the height of the cervical epithelium in *Pgr^f/f^* (65.8 ± 4.2 μm) and *Pgr^ed/ed^* mice (66.6 ± 2.9 μm) (Figure [1C](#F1){ref-type="fig"}). The cervical epithelium height in E~2~+P~4~−treated *Pgr^f/f^* (57.5 ± 5.0 μm) and *Pgr^ed/ed^* mice (60.7 ± 4.6 μm) was not significantly different from genotype−matching mice treated with E~2~ alone. The nucleus/cytoplasm ratio (0.66 ± 0.03) of cervical suprabasal cells in E~2~−treated *Pgr^f/f^* mice was significantly smaller than the ratio (1.09 ± 0.06) in E~2~+P~4~−treated mice (*P* = 0.05). A similar difference was observed in *Pgr^ed/ed^* mice \[0.66 ± 0.02 (E~2~) *vs*. 1.03 ± 0.01 (E~2~+P~4~); *P* = 0.05\]. Hydropic degeneration was prominent in the cervix of E~2~+P~4~−treated *Pgr^f/f^* but not *Pgr^ed/ed^* mice (Figure [1C](#F1){ref-type="fig"}). E~2~ induced hyperplasia and keratinization in the vaginal epithelium of *Pgr^f/f^* and *Pgr^ed/ed^* mice (Figure [1D](#F1){ref-type="fig"}). In the vaginal epithelium of E~2~+P~4~−treated *Pgr^f/f^* mice, keratinization was absent and hydropic degeneration was observed (Figure [1D](#F1){ref-type="fig"}). Also found was infiltration of K14−negative non−epithelial cells ([Supplementary Figure S2](#SD1){ref-type="supplementary-material"}), which are likely neutrophils \[[@R18]\]. These P~4~−induced histologic changes in the vaginal epithelium were absent in E~2~+P~4~−treated *Pgr^ed/ed^* mice (Figure [1D](#F1){ref-type="fig"}). E~2~ induced hyperplasia in the uterine epithelium, which was reversed by P~4~ in both *Pgr^f/f^* and *Pgr^ed/ed^* mice (Figure [1E](#F1){ref-type="fig"}). Phenotypes described in this study are summarized in Table [1](#T1){ref-type="table"}.

![Histology of female reproductive tracts in epithelial PR−deficient mice treated with E~2~+P~4~\
**A.** Epithelium−specific deletion of PR. Serial sections of the cervix, vagina, and uterus were stained for PR (brown). Nuclei were counterstained with hematoxylin. Black lines separate cervical/vaginal squamous epithelium (ep) and uterine luminal (le)/glandular epithelium (ge) from stroma (st). Scale bar, 50 μm. **B.** Schematics of murine female reproductive tracts. All analyses were carried out with red−boxed areas of each tissue. Note that a region between the cervix and uterus is not annotated because there is no histological boundary. **C.**-**E.** Ovariectomized mice were treated with female sex hormones as indicated and paraffin sections of the cervix **C.**, vagina **D.**, and uterus **E.** were subjected to H&E staining. Black arrowheads in **C.** and **D.** indicate cells undergoing hydropic degeneration. Green arrowheads in **D.** indicate non−epithelial cells. Representative images of each group are shown (*n* = 3-5). V, vehicle; E~2~, estradiol; P~4~, progesterone, Scale bar, 30 μm.](oncotarget-07-17455-g001){#F1}

###### Summary of P~4~−induced phenotypes in the female reproductive tract[^1^](#tfn_001){ref-type="table-fn"}
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Shown are phenotypes in epithelial PR--sufficient (*Pgrf/f*) and --deficient (*Pgred/ed*) mice treated with E~2~ and E~2~+P~4~. 2Nucleus to cytoplasm ratio. ++, high; +, low; −, rare/absent.

P~4~ fails to inhibit epithelial cell proliferation in the cervix and vagina, but not uterus of *Pgr^ed/ed^* mice {#s2_2}
-----------------------------------------------------------------------------------------------------------------

P~4~ inhibits epithelial cell proliferation in the female reproductive tract \[[@R15], [@R19]\]. We sought to determine whether epithelial PR is required for this effect. We analyzed expression of cell proliferation marker Ki67 to measure cell proliferation. Less than 1% of cervical epithelial cells were proliferative in vehicle−treated *Pgr^f/f^* and *Pgr^ed/ed^* mice (Figure [2A-2B](#F2){ref-type="fig"}). E~2~−induced cervical epithelial cell proliferation was not different between the two genotypes. Compared to genotype−matching mice treated with E~2~ alone, cervical epithelial cell proliferation in the basal layer was significantly decreased in E~2~+P~4~−treated *Pgr^f/f^* but not *Pgr^ed/ed^* mice (Figure [2A-2B](#F2){ref-type="fig"}). Similar phenotypes were observed in the vaginal epithelium of *Pgr^f/f^* and *Pgr^ed/ed^* mice (Figure [2C-2D](#F2){ref-type="fig"} and Table [1](#T1){ref-type="table"}). In the uteri of both *Pgr^f/f^* and *Pgr^ed/ed^* mice, E~2~−induced epithelial cell proliferation was significantly inhibited by P~4~ (Figure [2E-2F](#F2){ref-type="fig"}). In both genotypes, however, stromal cell proliferation was increased in the uteri of E~2~+P~4~−treated mice compared to E~2~−treated mice (Figure [2F](#F2){ref-type="fig"}). Similar results were obtained in the columnar epithelium of the cervix (data not shown). These results indicate that, under the same hormonal condition, epithelial PR is required for P~4~−induced suppression of cell proliferation only in the cervical and vaginal squamous epithelium.

![Epithelial PR is required for P~4~ to inhibit epithelial cell proliferation in the cervix and vagina, but not uterus\
Ovariectomized mice were treated with female sex hormones as indicated. Paraffin sections of the cervix **A.**, vagina **C.**, and uterus **E.** were stained for Ki67 (green). Nuclei were stained with Hoechst 33342 (blue). Scale bars, 30 μm. Results were quantified as described in *Materials & Methods*. Quantified results of the cervix **B.**, vagina **D.**, and uterus **F.** are shown as mean ± S.E.M (*n* = 3-5 per group). \**P* ≤ 0.01, \*\**P* ≤ 0.05.](oncotarget-07-17455-g002){#F2}

Epithelial PR is required for proper differentiation of cervical and vaginal squamous epithelial cells {#s2_3}
------------------------------------------------------------------------------------------------------

Histological features observed in the cervical and vaginal epithelium (*see* Figure [1C-1D](#F1){ref-type="fig"}) suggested that P~4~ regulates differentiation of squamous cells. Thus, we carried out Alcian blue staining and immunohistochemistry for cytokeratin 10 (K10), squamous differentiation marker \[[@R20]\]. Alcian blue staining is typically used to detect cervical acidic mucins, which are expressed by differentiated cells \[[@R21]\]. As expected, E~2~ induced expression of K10 in the suprabasal layer in the cervical epithelia of *Pgr^f/f^* and *Pgr^ed/ed^* mice (Figure [3A](#F3){ref-type="fig"}). K10 expression was reduced in the cervical epithelia of E~2~+P~4~−treated *Pgr^f/f^* and *Pgr^ed/ed^* mice, indicating that epithelial PR is dispensable for K10 suppression by P~4~. Alcian blue staining was prominent in the cervix of *Pgr^f/f^* mice treated with E~2~+P~4~, but absent in identically treated *Pgr^ed/ed^* mice (Figure [3B](#F3){ref-type="fig"}). This result indicates that P~4~−promoted Alcian blue staining is dependent upon epithelial PR. P~4~ inhibited E~2~−induced K10 expression and increased Alcian blue staining in the vaginal epithelium of *Pgr^f/f^* but not *Pgr^ed/ed^* mice (Figure [3C-3D](#F3){ref-type="fig"} and Table [1](#T1){ref-type="table"}). These results indicate that epithelial PR is required for P~4~−mediated regulation of squamous cell differentiation in the vagina to the greater extent than in the cervix.

![Epithelial PR is required for P~4~−mediated regulation of differentiation in the cervical and vaginal epithelium\
Reproductive tracts were isolated from female mice that were ovariectomized and then treated as indicated. Representative images of each group are shown (*n* = 3). **A.** Epithelial PR is dispensable for suppression of K10 expression by P~4~ in the cervical epithelium. Cervical sections were stained for K10 (green) and nuclei were stained with Hoechst 33342 (blue). Dotted lines separate epithelium (ep) and stroma (st). Scale bar, 50 μm. **B.** Alcian blue staining is increased by P~4~ in an epithelial PR−dependent manner in the cervical epithelium. Cervical sections were stained with Alcian blue. Nuclei were counterstained with Nuclear Fast Red. Scale bar, 50 μm. **C.** Epithelial PR is necessary for suppression of K10 expression by P~4~ in the vaginal epithelium. Vaginal sections were stained for K10 (green) and nuclei were stained with Hoechst 33342 (blue). Scale bar, 50 μm. **D.** Alcian blue staining is increased by P~4~ in an epithelial PR−dependent manner in the vaginal epithelium. Vaginal sections were subjected to Alcian blue staining. Nuclei were counterstained with Nuclear Fast Red. Scale bar, 50 μm.](oncotarget-07-17455-g003){#F3}

Epithelial PR plays distinct roles in epithelial apoptosis in the lower and upper reproductive tracts {#s2_4}
-----------------------------------------------------------------------------------------------------

P~4~ inhibits apoptosis in the uterine epithelium \[[@R16]\]. We carried out TUNEL assays to determine the role of P~4~ and epithelial PR in regulation of apoptosis in the cervix, vagina, and uterus. A few TUNEL−positive apoptotic cells were found in the cervical epithelium of vehicle− and E~2~−treated *Pgr^f/f^* and *Pgr^ed/ed^* mice (Figure [4A-4B](#F4){ref-type="fig"}). Compared to E~2~−treated mice, the apoptotic index was increased in the cervical epithelium of E~2~+P~4~−treated *Pgr^f/f^* but not *Pgr^ed/ed^* mice (Figure [4A-4B](#F4){ref-type="fig"}). Similar results were obtained in the vaginal epithelium (Figure [4C-4D](#F4){ref-type="fig"} and Table [1](#T1){ref-type="table"}). E~2~ induced apoptosis in the uterine epithelium regardless of the genotype, which was inhibited by P~4~ in both *Pgr^f/f^* and *Pgr^ed/ed^* mice (Figure [4E-4F](#F4){ref-type="fig"} and Table [1](#T1){ref-type="table"}). These results indicate that epithelial PR is required for P~4~−induced apoptosis in the epithelium of lower reproductive tracts (i.e., cervix and vagina), but dispensable for P~4~ to inhibit apoptosis in the uterine epithelium.

![Epithelial PR is required for P~4~−mediated regulation of apoptosis in the cervix and vagina, but not the uterus\
Reproductive tracts were isolated from female mice that were ovariectomized and then treated as indicated. **A.** P~4~ induces apoptosis in the cervical epithelium through epithelial PR. Cervical sections were subjected to TUNEL staining (green). Nuclei were stained with Hoechst 33342 (blue). Dotted lines separate epithelium (ep) and stroma (st). Scale bar, 50 μm. **B.** Results shown in **A.** were quantified. Results are shown as mean ± S.E.M (*n* = 3-5 per group). \**P* = 0.04. **C.** P~4~ induces apoptosis in the vaginal epithelium through epithelial PR. Vaginal sections were subjected to TUNEL staining (green). Scale bar, 50 μm. **D.** Results shown in **C.** were quantified and displayed as mean ± S.E.M (*n* = 3-5 per group). \**P* = 0.04. **E.** P~4~ prevents apoptosis in an epithelial PR−independent manner in the uterine epithelium. Uterine sections were subjected to TUNEL staining (green). Scale bar, 50 μm. **F.** Results shown in **E.** were quantified and displayed as mean ± S.E.M (*n* = 3 per group). \**P* = 0.05.](oncotarget-07-17455-g004){#F4}

ERα DBD and AF2 are required for upregulation of *Pgr* in the cervix and vagina {#s2_5}
-------------------------------------------------------------------------------

ERα regulates transcription of *Pgr* in the vagina and uterus \[[@R5]\]. We found that E~2~ increased the *Pgr* mRNA level significantly in the cervix of *Esr1^+/+^* but not *Esr1^−/−^* mice (Figure [5A](#F5){ref-type="fig"}). Similarly, PR protein was readily detected in cervical tissue extracts and paraffin sections derived from *Esr1^+/+^* but not *Esr1^−/−^* mice (Figure [5B-5C](#F5){ref-type="fig"}). These results demonstrate that ERα activates transcription of *Pgr* in the cervix. To understand a mechanism of transcriptional activation of *Pgr* by ERα, we made use of knock−in mouse models expressing ERα mutant defective for DBD, AF1, or AF2 (Figure [5D](#F5){ref-type="fig"}). The *AA* allele expresses an ERα mutant (E207A/G208A) that lacks the ERE−binding activity \[[@R22]\]. The *AF2* allele expresses ERα harboring L543A/L544A substitution mutations in the helix 12, which abrogates the AF2 function \[[@R23]\]. The *neo* allele has a neo cassette in the exon 2, which is designed to abrogate expression of ERα \[[@R24]\]. This allele, however, expresses truncated ERα proteins lacking the AF1 domain due to cryptic splicing events \[[@R25], [@R26]\]. PR expression was barely detectable in cervical tissue extracts obtained from *Esr1^AA/−^* and *Esr1^AF2/AF2^* mice (Figure [5B](#F5){ref-type="fig"}). Similarly, E~2~ failed to induce PR expression in the cervix of *Esr1^AA/−^* and *Esr1^AF2/AF2^* mice (Figure [5C](#F5){ref-type="fig"}). Albeit reduced compared to *Esr1^+/+^* mice, the PR level was increased in cervical tissue extracts from *Esr1^neo/neo^* mice compared to *Esr1^−/−^*, *Esr1^AA/−^*, and *Esr1^AF2/AF2^* mice (Figure [5B](#F5){ref-type="fig"}). Upregulation of PR expression in the cervix of *Esr1^neo/neo^* mice was mostly restricted in the stroma (Figure [5C](#F5){ref-type="fig"}). E~2~ did not activate *Pgr* expression in the vagina of *Esr1^−/−^*, *Esr1^AA/−^*, *Esr1^AF2/AF2^*, and *Esr1^neo/neo^* mice ([Supplementary Figure S3](#SD1){ref-type="supplementary-material"}). PR expression patterns were similar in the cervix and vagina of *Esr2^+/+^* and *Esr2^−/−^* mice ([Supplementary Figure S4](#SD1){ref-type="supplementary-material"}), indicating that ERβ is not required for upregulation of *Pgr*. To determine whether stroma−epithelium cross talk is involved in upregulation of *Pgr* by E~2~−ERα, we used *Wnt7a−Cre/Esr1^f/f^* (referred to as *Esr1^ed/ed^* hereafter). ERα expression was efficiently ablated in epithelial but not stromal cells in the cervix and vagina of *Esr1^ed/ed^* mice (Figure [5E](#F5){ref-type="fig"}). While E~2~ induced PR expression in the cervical stroma of *Esr1^f/f^* and *Esr1^ed/ed^* mice, E~2~ failed to do so in the cervical epithelium of *Esr1^ed/ed^* mice (Figure [5F](#F5){ref-type="fig"}). Similar results were obtained from the vagina (Figure [5G](#F5){ref-type="fig"}). These results suggest that, in the cervix and vagina, E~2~−induced upregulation of *Pgr* is cell−autonomous and mediated commonly by ERα DBD (i.e., ERE−binding) and AF2.

![Mechanisms of upregulation of *Pgr* by ERα in the cervix and vagina\
**A.** *Pgr* is upregulated by E~2~−ERα in the cervix. Mice were ovariectomized and treated with E~2~ for 24 hr. The relative levels of *Pgr* mRNA were compared by qPCR. The value from vehicle−treated *Esr1*^+/+^ cervix was set at 1. Results are shown as mean ± S.E.M (*n* = 3). \**P* = 0.05. **B.** Upregulation of PR expression is absent in the cervix of *Esr1*^AA/−^ and *Esr1*^AF2/AF2^ mice. Ovary−intact mice of indicated genotypes (8-12 weeks of age) were treated with E~2~ for 3 days to synchronize mice at the estrus. Expression of PR in the cervix was determined by immunoblot. *Pgr*^−/−^ tissue extracts were used as negative control. GAPDH was used as loading control. Results were taken from separate gels indicated by black boxes. Intervening lanes in a same gel were removed, which was indicated by vertical white lines. Representative results from more than 2 mice per genotype are shown. **C.** E~2~−induced PR expression is absent in the cervix of *Esr1*^AA/−^ and *Esr1*^AF2/AF2^ mice. Ovariectomized mice (*n* = 3 per group) were treated with vehicle or E~2~ for 7 days. Cervical tissue sections were stained for PR (green). Nuclei were stained with Hoechst 33342 (blue). Dotted lines separate epithelium (ep) and stroma (st). Scale bar, 25 μm. **D.** Summary of ERα proteins expressed by *Esr1* alleles used in the study. Asterisks denote locations of alanine substitution mutations. AF, activation function; DBD, DNA−binding domain; LBD, ligand−binding domain. **E.** *Esr1* is deleted in the cervical and vaginal epithelium. Cervical and vaginal sections (*n*= 3 per tissue) were stained for ERα (green). Nuclei were stained with Hoechst 33342 (blue). Scale bar, 50 μm. **F.**-**G.** Epithelial ERα is required for upregulation of epithelial *Pgr* in the lower reproductive tracts. Mice (*n* = 3 per group) were ovariectomized and treated with vehicle or E~2~. Tissue sections of the cervix **F.** and vagina **G.** were stained for PR (green). Nuclei were stained with Hoechst 33342 (blue). Scale bar, 50 μm.](oncotarget-07-17455-g005){#F5}

ERα DBD and AF2 are required for upregulation of stromal *Pgr* and downregulation of epithelial *Pgr* in the uterus {#s2_6}
-------------------------------------------------------------------------------------------------------------------

Consistent with previously published results \[[@R13]\], expression of ERα was lost in the epithelium but retained in the stroma of the *Esr1^ed/ed^* uteri (Figure [6A](#F6){ref-type="fig"}). While stromal PR expression was increased by E~2~ in the *Esr1^f/f^* and *Esr1^ed/ed^* uteri, E~2~ decreased the PR levels in the uterine epithelium in both genotypes (Figure [6B](#F6){ref-type="fig"}). This result confirmed the paracrine mechanism of *Pgr* downregulation by ERα in the uterine epithelium \[[@R5], [@R27]\]. Stromal upregulation and epithelial downregulation of *Pgr* by E~2~ were absent in the uterus of *Esr1^−/−^*, *Esr1^AA/−^*, and *Esr1^AF2/AF2^* mice (Figure [6C](#F6){ref-type="fig"}). As reported previously \[[@R5]\], E~2~ activated stromal *Pgr* expression but failed to downregulate epithelial *Pgr* in the uterus of *Esr1^neo/neo^* mice (Figure [6C](#F6){ref-type="fig"}). In the *Esr2^−/−^* uterus, E~2~ increased and decreased stromal and epithelial PR expression, respectively ([Supplementary Figure S4](#SD1){ref-type="supplementary-material"}), indicating that ERβ is not required for regulation of *Pgr* in the uterus. These results indicate that the function of ERα DBD and AF2 in stromal cells is required for stromal upregulation and epithelial downregulation of *Pgr* in the uterus.

![Mechanisms of regulation of *Pgr* by ERα in the uterus\
**A.** *Esr1* is deleted in the uterine epithelium. Uterine sections (*n* = 3) were stained for ERα (green). Nuclei were stained with Hoechst 33342 (blue). Dotted lines separate luminal epithelium (le) and stroma (st). Glandular epithelia (ge) are circumscribed by red circles. Scale bar, 50 μm. **B.** E~2~ suppresses epithelial *Pgr* expression in the *Esr1*^ed/ed^ uteri. Mice (*n* = 3) were ovariectomized and treated with vehicle or E~2~. Uterine tissue sections were stained for PR (green). Nuclei were stained with Hoechst 33342 (blue). Dotted lines separate luminal epithelium (le) and stroma (st). Glandular epithelia (ge) are circumscribed by red circles. Note that E~2~ downregulates epithelial *Pgr* and upregulates stromal *Pgr* in both genotypes. Scale bar, 25 μm. **C.** ERα DBD and AF2 are required for *Pgr* regulation in the uterus. Mice were treated as described in **B.**. Uterine tissue sections (*n* = 3 per group) were stained for PR (green). Nuclei were stained with Hoechst 33342 (blue). Dotted lines are to separate luminal (le) and glandular epithelium (ge) from stroma (st). Scale bar, 30 μm.](oncotarget-07-17455-g006){#F6}

We next analyzed binding of ERα to the *Pgr* gene using the previously published ERα ChIP−seq data \[[@R28], [@R29]\]. Approximately 200 kb upstream and 100 kb downstream of the *Pgr* transcription start site (TSS) were analyzed for the binding of wild−type ERα. While there were two E~2~−independent ERα−binding peaks at the 3′ end of the *Pgr* gene, E~2~ enhanced ERα binding to the intragenic regions and −72 kb and −155 kb cluster in the *Esr1^+/+^* uterus (Figure [7A](#F7){ref-type="fig"}). E~2~ also increased RNA polII binding to the *Pgr* gene in the same tissue. While the −155 kb cluster was closer to *AK054106*, E~2~ did not regulate this gene (data not shown). Notably, we identified predicted half or full EREs in all ERα−binding sites (Figure [7A](#F7){ref-type="fig"}). Consistently, in the uterus of *Esr1^AA/−^* mice, both E~2~−dependent and −independent ERα binding to the *Pgr* locus were not observed (Figure [7A](#F7){ref-type="fig"}). Concordantly, E~2~−induced recruitment of RNA polII was absent in the *Esr1^AA/−^* uterus. We confirmed by ChIP followed by qPCR that E~2~ induced enrichment of ERα binding to the −62 kb region (7.1-fold) and intron 3-4 (6.2-fold) of *Pgr* in the uterus of *Esr1^+/+^* but not *Esr1^AA/−^* mice (Figure [7B](#F7){ref-type="fig"}). These results suggest that, in the uterus, ERα activates transcription of *Pgr* mainly by binding to EREs.

![ERα binding to EREs correlates with RNA polII recruitment to the *Pgr* locus in the uterus\
**A.** E~2~ induces binding of ERα and RNA polII to *Pgr* in the uterus of *Esr1*^+/+^ but not *Esr1*^AA/−^ mice. Recruitment of ERα and RNA polII to the *Pgr* locus was analyzed using ChIP−seq data available in Gene Expression Omnibus (*Esr1*^+/+^, GSE36455l; *Esr1*^AA/−^, GSE56466). Vertical blue lines at the top indicate locations of predicted EREs, which were identified using position weight matrix algorithm. Two peaks validated in **B.** are indicated by red asterisk. Pink boxes indicate −155 kb (1) and −72 kb cluster (2). **B.** Validation of E~2~−dependent enrichment of ERα at two candidate binding regions. Mice were ovariectomized and treated with vehicle or E~2~. Extracted chromatin was subjected to ERα ChIP and enrichment of approximately 62 kb upstream of the *Pgr* TSS and intron 3-4 were quantified by qPCR. Data normalized to % input DNA is shown as mean ± S.E.M. (*n* = 4-5). \**P* = 0.001; \*\**P* = 0.0005.](oncotarget-07-17455-g007){#F7}

DISCUSSION {#s3}
==========

P~4~ inhibits E~2~−promoted epithelial cell proliferation in the murine female reproductive tract \[[@R19], [@R30]\]. We showed that, under the same hormonal condition, epithelial PR was necessary for P~4~ to suppress E~2~−induced epithelial cell proliferation in the cervix and vagina, but dispensable in the uterus (Figure [2](#F2){ref-type="fig"}). It is shown that epithelial PR is required for P~4~−mediated inhibition of uterine epithelial cell proliferation \[[@R30]\]. This discrepancy may be due to differences in treatment design (P~4~ for 3 days and then E~2~+P~4~ for 1 day *vs*. E~2~+P~4~ for 7 days), E~2~ doses (50 ng *vs*. 1 μg), mouse genetic background (B6.SJL.129 mixed *vs*. FVB) and/or housing environment. We note that 7−day treatment with E~2~ and P~4~ might be pharmacologic rather than physiologic. Nonetheless, we believe our results are biologically relevant because P~4~−mediated inhibition of uterine epithelial proliferation during pregnancy depends on Hand2 transcription factor \[[@R31]\]. Expression of Hand2 depends on P~4~ and PR and is restricted in the uterine stroma \[[@R31]\].

P~4~ inhibited E~2~−induced apoptosis in the uterus of both *Pgr^f/f^* and *Pgr^ed/ed^* mice (Figure [4E-4F](#F4){ref-type="fig"}). It is consistent with that P~4~ prevents epithelial cell apoptosis in the tissue recombinant composed of *Pgr^+/+^* stroma and *Pgr^−/−^* epithelium \[[@R16]\]. E~2~ induces apoptosis in the uterine epithelium of *Esr1^f/f^* and *Esr1^ed/ed^* mice \[[@R13]\]. These results suggest that stromal ERα promotes and stromal PR inhibits apoptosis of uterine epithelial cells. One possibility is that stromal PR activates expression of a paracrine factor(s) that promotes cell survival. PR interacts with ERα and modulates the function of ERα in breast cancer cells \[[@R32]\]. Another possibility is that PR interacts with ERα in uterine stromal cells and inhibits ERα−mediated expression of a pro−apoptotic secretory factor(s). In the rodent uterus, E~2~−induced hyperplasia is eliminated by apoptosis \[[@R33]\]. Perhaps, E~2~−induced apoptosis is to balance out E~2~−induced hyperproliferation of uterine epithelial cells. Consistent with this idea, the apoptotic index was correlated with the proliferative index in the uterine epithelium (Figure [2F](#F2){ref-type="fig"} and [4F](#F4){ref-type="fig"}). Unlike the uterus, P~4~ promoted apoptosis in the cervical and vaginal epithelium, which was dependent on epithelial PR (Figure [4A-4D](#F4){ref-type="fig"}). Epithelial PR was necessary for P~4~ to increase the ratio of nucleus to cytoplasm and suppress expression of K10 in the vagina but not cervix (Table [1](#T1){ref-type="table"}). These results reveal that epithelial PR is differentially required for P~4~ responses of epithelial cells in the cervix, vagina, and uterus.

Using mouse genetic models, we determined that ERE binding (i.e., classical mechanism) of ERα is required for upregulation of *Pgr* in the cervix, vagina, and uterus (Figure [5B-5D](#F5){ref-type="fig"}, [6C](#F6){ref-type="fig"}, [7](#F7){ref-type="fig"} and [Supplementary Figure S3](#SD1){ref-type="supplementary-material"}). The ERα DBD mutant (E207A/G208A) has acquired the capability to bind hormone response elements such as progesterone response element \[[@R29]\]. We do not believe that the gain−of−function compromises our conclusion because this ERα mutant did not bind to the *Pgr* locus (Figure [7](#F7){ref-type="fig"}). It is possible that the ChIP−seq analyses might have failed to identify weak ERα−binding sites; thus, we cannot rule out a possibility that the ERα tethering mechanism also contributes to transcription of *Pgr* in the female reproductive tract. Knock−in mice expressing an ERα mutant defective for the tethering mechanism would be required to test this. Reporter assays have shown that AP-1 and Sp-1 sites at the promoter downstream are required for ERα−mediated *PGR* activation in MCF7 breast cancer cells \[[@R7], [@R8]\]. In the uterus, strong E~2~−induced DBD−dependent ERα binding occurred mostly at far upstream (\> 60 kb) of the *Pgr* gene (Figure [7A](#F7){ref-type="fig"}). Genome−wide enrichment of ERα binding to promoter−distal regions has been identified \[[@R28], [@R34]\]. ERE−dependent long−range activation of *PGR* by ERα has been demonstrated in MCF7 cells \[[@R6]\]. It is likely that ERα binding to *Pgr* in the uterus occurs in stromal cells because epithelial ERα was not required for upregulation of stromal *Pgr* and downregulation of epithelial *Pgr* (Figure [6B](#F6){ref-type="fig"}). We postulate that similar long−range regulation by ERα is involved in transcriptional activation of *Pgr* in the cervix and vagina. The AF2 domain was also required for upregulation of *Pgr* by ERα in the cervix, vagina, and uterus (Figure [5B-5D](#F5){ref-type="fig"}, [6C](#F6){ref-type="fig"} and [Supplementary Figure S3](#SD1){ref-type="supplementary-material"}). Upregulation of *Pgr* was evident in the cervical and uterine stroma, but not vagina of *Esr1^neo/neo^* mice (Figure [5C](#F5){ref-type="fig"}, [6C](#F6){ref-type="fig"} and [Supplementary Figure S3](#SD1){ref-type="supplementary-material"}). In tissue recombinants derived from *Esr1^neo/neo^* mice, PR expression is induced by E~2~ in the uterine but not vaginal stroma \[[@R5]\]. These results indicate that (1) ERα DBD and AF2 are commonly required for activation of *Pgr* in the female reproductive tracts and (2) AF1 is required for upregulation of *Pgr* only in the vaginal and cervical epithelium and vaginal stroma. Differential requirement of ERα domains for activation of *Pgr* may be due to distinct chromatin structures in different tissues and cell types, which may require different coactivators \[[@R2], [@R35]\].

E~2~ suppressed expression of *Pgr* in the uterine epithelium *via* stromal ERα (Figure [6B](#F6){ref-type="fig"}), which is in agreement with other findings \[[@R5], [@R13]\]. Downregulation of *Pgr* in the uterine epithelium involves transcriptional repression \[[@R5], [@R27]\]. It is unlikely that the non−cell autonomous downregulation of *Pgr* is through a cell−cell contact because epithelial and stromal cells are physically separated by the basement membrane. Thus, we postulate that a paracrine factor(s) produced by stromal cells is responsible for repression of *Pgr* in the uterine epithelium. ERα DBD, AF1, and AF2 were required for downregulation of *Pgr* in the uterine epithelium (Figure [6C](#F6){ref-type="fig"}), further suggesting that ERα DBD, AF1, and AF2 are necessary for regulating expression of such a factor(s). The AP-1 site at the +745 bp region of *PGR* has been implicated in repression of *PGR* in MCF7 cells \[[@R9]\]. It is plausible that a paracrine factor activates AP-1, which in turn suppresses transcription of *Pgr* in the uterine epithelium.

Our results demonstrate distinct functions of epithelial PR in the cervix, vagina, and uterus, suggesting that PR regulates unique sets of genes and pathways in these tissues. Warranted are further studies to identify PR target genes and pathways in the stroma and epithelium of these tissues. Our results also demonstrate unique mechanisms of *Pgr* regulation in the cervix, vagina, and uterus. Together, our results underscore the complexity of function and regulation of *Pgr* in the female reproductive tracts.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

Investigation has been conducted in accordance with the ethical standards and according to national and international guidelines. All procedures were carried out according to animal protocols approved by the University of Houston Institutional Animal Care and Use Committee.

Mice and treatments {#s4_2}
-------------------

All *Esr1* and *Pgr* mice as well as *Esr2* knockout and *Wnt7a-Cre* transgenic mice were described previously \[[@R13], [@R22]--[@R24], [@R36]--[@R39]\], and genotyped by PCR. All mouse strains except for *Esr2* knockout mice (C57BL/6) were backcrossed to FVB at least 5 generations. Mice were ovariectomized at the age of 6-8 weeks and rested for 2 weeks. They were then i.p. injected with vehicle, 17β-estradiol (E~2~) alone, or E~2~ (1 μg/day) plus P~4~ (1 mg/day) for 7 days.

Histological staining {#s4_3}
---------------------

The female reproductive tracts were harvested 24 hours after final hormone injections and processed as described previously \[[@R19]\]. Hematoxylin & eosin (H&E) and Alcian blue staining were carried out as described previously \[[@R19]\].

Immunohistochemistry and immunoblot {#s4_4}
-----------------------------------

Antibodies were purchased from Santa Cruz Biotechnology \[ERα (H184), PR (H190) and GAPDH (V-18)\], Thermo Scientific \[Ki67 (clone SP6) and K10 (clone DE-K10)\], BioLegend (K14), GenDEPOT (HRP−conjugated anti−rabbit/goat IgG), Life Technologies (Alexa488−conjugated anti−rabbit/mouse IgG) and Rockland Immunochemicals (biotinylated anti−rabbit IgG). For IHC, sections were deparaffinized, rehydrated, microwaved in 10 mM sodium citrate buffer (pH 6.0) and incubated with primary antibodies diluted in blocking buffers (PR, 1:200 in 5% goat serum; ERα, 1:100 in 10% goat serum and 0.5% skim milk; Ki67, 1:100 in 10% goat serum; K10, 1:50 in 5% goat serum). After extensive washes, sections were incubated with Alexa488−conjugated anti−rabbit/mouse IgG or biotinylated anti−rabbit IgG followed by ABC complex (Vector Laboratories) as described previously \[[@R19]\]. For immunoblot, cervical tissue homogenates were resolved in 7.5% SDS−polyacrylamide gel and proteins were transferred to PVDF membranes.

TUNEL assay {#s4_5}
-----------

TUNEL staining was carried out using ApopTag Fluorescein *in situ* apoptosis detection kit (Millipore) according to the manufacturer\'s instructions.

Microscopy and digital image analyses {#s4_6}
-------------------------------------

Stained tissue sections were visualized by an Olympus BX51 or a Nikon ECLIPSE Ti microscope, and photographed with a color camera (Olympus DP73) or cooled CCD monochrome cameras (Olympus XM10 and Photometrics CoolSNAP HQ2). Digital images were acquired with imaging software (Olympus cellSens Dimension and Nikon NIS-Elements AR). For quantification, images were acquired from 5 microscopic fields per tissue with a 20X objective lens, and cells were quantified using the counting function of the NIH ImageJ software. Typical ranges of total cell count per tissue were 400 - 600 in the basal layer and 1,500 - 2,000 in the suprabasal layers.

Chromatin immunoprecipitation and quantitative real−time PCR {#s4_7}
------------------------------------------------------------

Chromatin was prepared from ovariectomized *Esr1^+/+^* or *Esr1^AA/−^* uterus one hour after i.p. injection with saline or E~2~ (250 ng/mouse) and ERα was immunoprecipitated as described previously \[[@R29]\]. Candidate ERα−binding regions in the *Pgr* locus were amplified using qPCR as described previously \[[@R29]\]. Nanograms of amplimer DNA was calculated using a standard curve, and normalized to % input DNA for each sample. Primers for the −62 kb region were 5′-GGGTCGAAACTACCAGCTAAA-3′ (forward) and 5′-CAAAGGCTTGGACAAATGAA-3′ (reverse). Primers for intron 3-4 were 5′-TCTGCTCCAATGACTGTGTTC-3′ (forward) and 5′-ATCACATGCACTGAGAAGATCA-3′ (reverse). To compare expression levels of *Pgr* mRNA in the cervix, qPCR was carried out using a SYBR Green detection method. The relative mRNA levels were calculated using the ΔΔC~t~ method with *Ppia* mRNA as control. Primers for *Pgr* were 5′-CCAGCATGTCGTCTGAGAAA-3′ (forward) and 5′-GCCTGGCTCTCGTTAGGAAG-3′ (reverse). Primers for *Ppia* were 5′-GGGTTCCTCCTTTCACAGAA-3′ (forward) and 5′-GATGCCAGGACCTGTATGCT-3′ (reverse).

Statistical analyses {#s4_8}
--------------------

Wilcoxon rank sum test was used for analysis of cell proliferation and apoptosis. Student\'s *t*-test or 2-way ANOVA with Fisher\'s LSD was used for analysis of qPCR data.
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